Matrix metalloproteinases as modulators of inflammation and innate immunity

Nature Reviews Immunology

Volumn 4, Issue 8, 2004, Pages 617-629

  Parks, William C ^a,b   Wilson, Carole L ^b   López Boado, Yolanda S ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AE 941; ALPHA 2 MACROGLOBULIN; BISPHOSPHONIC ACID DERIVATIVE; CATECHIN; CHEMOKINE; COLLAGENASE 3; DOXYCYCLINE; DOXYCYCLINE HYCLATE; GELATINASE A; GELATINASE B; HYDROXAMIC ACID DERIVATIVE; INTERLEUKIN 13; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; NATURAL PRODUCT; NEUTROPHIL COLLAGENASE; PRINOMASTAT; STROMELYSIN; TANOMASTAT; TETRACYCLINE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TUMOR NECROSIS FACTOR;

CARTILAGE; CATALYSIS; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SUBSTRATE; EPITHELIZATION; EXTRACELLULAR MATRIX; HUMAN; IMMUNE RESPONSE; IMMUNITY; INFLAMMATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PERIODONTAL DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SHARK; SKIN DISEASE; TEA; TISSUE REPAIR;

EID: 3543134126     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1418     Document Type: Review

References (144)

1. Velasco, G. et al. Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J. Biol. Chem. 274, 4570-4576 (1999).
2. Bode, W., Gomis-Ruth, F. X. & Stockler, W. Astacins, serralysins, snake venom and matrix metalloproteinases, exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the 'metzincins'. FEBS Lett. 331, 134-140 (1993).
3. Massova, I., Kotra, L. P., Fridman, R. & Mobashery, S. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J. 12, 1075-1095 (1998).
4. Shapiro, S. D. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr. Opin. Cell Biol. 10, 602-608 (1998).
5. Van Wart, H. E. & Birkedal-Hansen, H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. USA 87, 5578-5582 (1990).
6. Strongin, A. Y. et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. 270, 5331-5338 (1995).
7. Hernandez-Barrantes, S. et al. Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J. Biol. Chem. 275, 12080-12089 (2000).
8. Wang, Z., Juttermann, R. & Soloway, P. D. TIMP-2 is required for efficient activation of proMMP-2 in vivo. J. Biol. Chem. 275, 26411-26415 (2000).
9. Caterina, J. J. et al, Inactivating mutation of the mouse tissue inhibitor of metalloproteineses-2 (Timp-2) gene alters proMMP-2 activation. J. Biol. Chem. 275, 26416-26422 (2000).
10. Yang, Z., Strickland, D. K. & Bornstein, P. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J. Biol. Chem. 276, 8403-8408 (2001).
11. Barmina, O. Y. et al. Collagenase-3 binds to a specific receptor and requires the low density lipoprotein receptor-related protein for internalization. J. Biol. Chem. 274, 30087-30093 (1999).
12. Weiss, S. J., Peppin, G., Ortiz, X., Ragsdale, C. & Test, S. T. Oxidative autoactivation of latent collagenase by human neutrophils. Science 227, 747-749 (1985).
13. Peppin, G. J. & Weiss, S. J. Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils. Proc. Natl. Acad. Sci. USA 83, 4322-4326 (1986).
14. Fu, X., Kassim, S. Y., Parks, W. C. & Heinecke, J. W. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J. Biol. Chem. 276, 41279-41287 (2001).
15. Gu, Z. et al. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297, 1186-1190 (2002).
16. Fu, X., Kassim, S. Y., Parks, W. C. & Heinecke, J. W. Hypochlorous acid generated by myeloperoxidase modifies adjacent tryptophan and glycine residues in the catalytic domain of matrix metalloproteinase-7 (matrilsin): an oxidative mechanism for restraining proteolytic activity during inflammation. J. Biol. Chem. 278, 28403-28409 (2003). References 12-16 show that reactive metabolites, often leukocyte-generated oxidants, can both activate and inactivate the catalytic activity of MMPs. Although these mechanisms have not yet been shown in vivo, they are probably important for the regulation of MMPs in inflammation.
17. Sternlicht, M. D. & Werb, Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17, 463-516 (2001).
18. Mackay, A. R., Hartzler, J. L., Palina, M. D. & Thorgeirsson, U. P. Studies on the ability of 65-kDa and 92-kDa tumor cell gelatinases to degrade type IV collagen. J. Biol. Chem. 265, 21929-21934 (1990).
19. Halpert, I. et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc. Natl. Acad. Sci. USA 93, 9748-9753 (1996).
20. 3. Cell 85, 683-693 (1996).
21. 1 upon release from keratinocytes migrating on type I collagen. J. Biol. Chem. 276, 29368-29374 (2001).
22. 2 integrin I domain/procollagenase-1 (matrix metalloproteinase-1) interaction, J. Biol. Chem. 276, 29375-29381 (2001).
23. Yu, Q. & Stamenkovic, I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev. 14, 163-176 (2000).
24. Yu, W. H. & Woessner, J. F. Jr. Heparan sulfate proteoglycans as extracellular docking molecules for matrilysin (matrix metalloproteinase 7). J. Biol. Chem. 275, 4183-4191 (2000).
25. Yu, W. H., Woessner, J. F. Jr, McNeish, J. D. & Stamenkovic, I. CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev. 16, 307-323 (2002). This paper provides a good example of how a 'secreted' MMP is bound to and compartmentalized by a cell-surface molecule.
26. Gross, J. & Lapiere, C. M. Collagenolytic activity in amphipian tissues: a tissue culture assay. Proc. Natl Acad. Sci. USA 48, 1014-1022 (1962).
27. McQuibban, G.A. et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289, 1202-1206 (2000). This paper shows how exosite scanning and yeast two-hybrid techniques can be used to identify novel MMP substrates: in this case, chemokines. Together with other studies by these investigators (references 54 and 55), this study provides evidence that MMP proteolysis directly regulates chemokine activity.
28. Guo, L. et al. A proteomic approach for the identification of cell-surface proteins shed by metalloproteases. Mol. Cell Proteomics 1, 30-36 (2002).
29. Tam, E. M., Morrison, C. J., Wu, Y. I., Stack, M. S. & Overall, C. M. Membrane protease proteomics: isotopecoded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc. Natl Acad. Sci. USA 101, 6917-6922 (2004). This paper describes a proteomics study using state-of-the-art technology to identify MMP substrates. This knowledge is essential for understanding the function of these enzymes in vivo.
30. McCawley, L. J. & Matrisian, L. M. Matrix metalloproteinases: they're not just for matrix anymore! Curr. Opin. Cell Biol. 13, 534-540 (2001).
31. Holmbeck, K. et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99, 81-92 (1999).
32. Zhou, Z. et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc. Natl Acad. Sci. USA 97, 4052-4057 (2000).
33. Hotary, K., Allen, E., Punturieri, A., Yana, I. & Weiss, S. J. Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J. Cell Biol. 149. 1309-1323 (2000).
34. Hotary K. B. et al. Matrix metalloproteinases (MMPs) regulate fibrin-invasive activity via MT1-MMP-dependent and -independent processes. J. Exp. Med. 195, 295-308 (2002).
35. Filippov, S. et al. Matrilysin-dependent elastolysis by human macrophages. J. Exp. Med. 198, 925-935 (2003).
36. Opdenakker, G., Van den Steen, P. E. & Van Damme, J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 22, 571-579 (2001).
37. Nathan, C. Points of control in inflammation. Nature 420, 846-852 (2002).
38. Lee, H. M. et al. Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontits patients is enhanced when combined with a non-steroidal anti-inflammatory drug. J. Periodontol. 75, 453-463 (2004).
39. Whelan, C. J. Metalloprotease inhibitors as anti-inflammatory agents: an evolving target? Curr. Opin. Investig. Drugs 5, 511-516 (2004).
40. Sierevogel, M. J., Pasterkamp, G., de Kleijn, D. P. & Strauss, B. H. Matrix metalloproteinases: a therapeutic target in cardiovascular disease. Curr. Pharm. Des. 9, 1033-1040 (2003).
41. Itoh, T. et al. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J. Immunol. 169, 2643-2647 (2002).
42. Mudgett, J. S. et al. Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum. 41, 110-121 (1998).
43. Parks, W. C. Matrix metalloproteinases in repair. Wound Repair Regen. 7, 423-432 (1999).
44. Pilcher, B. K. et al. The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix. J. Cell Biol. 137, 1445-1457 (1997).
45. Dunsmore, S. E. et al. Matrilysin expression and function in airway epithelium. J. Clin. Invest. 102, 1321-1331 (1998).
46. McGuire, J. K., Li, O. & Pariks, W. C. Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am. J. Pathol. 162, 1831-1843 (2003).
47. Legrand, C. et al. Airway epithelial cell migration dynamics: MMP-9 role in cell-extracellular matrix remodeling. J. Cell Biol. 146, 517-529 (1999).
48. Betsuyaku, T., Fukuda, Y., Parks, W. C., Shipley, J. M. & Senior, R. M. Gelatinase B is required for alveolar bronchiolization after intratracheal bleomycin. Am. J. Pathol. 157, 525-535 (2000).
49. Saarialho-Kere, U. K., Crouch, E. C. & Parks, W. C. Matrix metalloproteinase matrilysin is constitutively expressed in human exocrine epithelium. J. Invest. Dermatol. 105, 190-196 (1995).
50. Ouellette, A. J. & Selsted, M. E. Paneth cell defensins: endogenous peptide components of intestinal host defense. FASEB J. 10, 1280-1289 (1996).
51. Wilson, C. L. et al. Regulation of intestinal α-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 286, 113-117 (1999). This study identifies α-defensins as a new class of substrates for MMPs and demonstrates a specific role for MMP7 in innate immunity.
52. Mulvey, M. A. et al. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 262, 1494-1497 (1998).
53. Powell, W. C., Fingleton, B., Wilson, C. L., Boothby, M. & Matrisian, L. M. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr. Biol. 9, 1441-1447 (1999). This study establishes that FASL is a substrate for MMP7. MMP-mediated apoptosis, through the activation of FASL, might provide a mechanism for bacterial clearance, as indicated in figure 4.
54. Hartzell, W. & Shapiro, S. D. Macrophage elastase prevents Gemella morbillorum infection and improves outcome following murine bone marrow transplantation. Chest 116, 31S-32S (1999).
55. López-Boado, Y. S. et al. Bacterial exposure induces and activates matrilysin in mucosal epithelial cells. J. Cell Biol. 148, 1305-1315 (2000).
56. López-Boado, Y. S., Wilson, C. L. & Parks, W. C. Regulation of matrilysin expression in airway epithelial cells by Pseudomonas aeruginosa flagellin. J. Biol. Chem. 276, 41417-41423 (2001).
57. Wilson, C. L. & Matrisian, L. M. Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int. J. Biochem. Cell Biol. 28, 123-136 (1996).
58. Kagnoff, M. F. & Eckmann, L. Epithelial cells as sensors for microbiol infection. J. Clin. Invest. 100, 6-10 (1997).
59. Borish, L. C. & Steinke, J. W. Cytokines and chemokines. J. Allergy Clin. Immunol. 111, S460-S475 (2003).
60. McQuibban, G. A. et al. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 100, 1160-1167 (2002).
61. McQuibban, G.A. etal. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J. Biol. Chem. 276, 43503-43508 (2001).
62. Van den Steen, P. E., Proost, P., Wuyts, A., Van Damme, J. & Opdenakker, G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-α and leaves RANTES and MCP-2 intact. Blood 96, 2673-2681 (2000).
63. Van Den Steen, P. E. et al. Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/UX and modulate their physiological activities. Eur. J. Biochem. 270, 3739-3749 (2003).
64. Corry, D. B. et al. Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency. Nature Immunol. 3, 347-353 (2002). One the first papers to show that MMPs establish chemokine gradients in vivo. Reference 71 is a follow-up to these studies.
65. Pruijt, J. F. et al. Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9). Proc. Natl Acad. Sci. USA 96, 10863-10868 (1999).
66. Li, Q., Park, P. W., Wilson, O. L. & Parks, W. C. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111, 635-646 (2002). This paper describes a mechanism in which three epithelial products - an MMP, a CXC-chemokine and a proteoglycan - interact to control and coordinate acute inflammation at sites of injury.
67. Zhang, K. et al. HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nature Neurosci. 6, 1064-1071 (2003). This interesting study shows that MMP2 secreted by HIV-infected macrophages cleaves CXCL12 to generate a potent neurotoxin.
68. Balbin, M. et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nature Genet. 35, 252-257 (2003).
69. Khandaker, M. H. et al. Metalloproteinases are involved in lipopolysaccharide- and tumor necrosis factor-α-mediated regulation of CXCR1 and CXCR2 chemokine receptor expression. Blood 93, 2173-2185 (1999).
70. Li, X. Y., Donaldson, K., Brown, D. & Macnee, W. The role of tumor necrosis factor in increased airspace epithelial permeability in acute lung inflammation. Am. J. Resp. Cell Mol. Biol. 13, 185-195 (1995).
71. Corry, D. B. et al. Overlapping and independent contributions of MMP2 and MMP9 to lung allergic inflammatory cell egression through decreased CC chemokines. FASEB J. 18, 995-997 (2004).
72. Haro, H. et al. Matrix metalloproteinase-3-dependent generation of a macrophage chemoattractant in a model of herniated disc resorption. J. Clin. Invest. 105, 133-141 (2000). Together with reference 102, this paper shows that specific MMPs function as crucial components of an inflammatory network between different cell types, using a model of tissue resorption.
73. Hautamaki, R. D., Kobayashi, D. K., Senior, R. M. & Shapiro, S. D. Requirement for macrophage elastase for cigarette smoke-induced emphysema. Science 277, 2002-2004 (1997).
74. Nelissen, I. et al. Gelatinase B/matrix metalloproteinase-9 cleaves interferon-β and is a target for immunotherapy. Brain 126, 1371-1381 (2003).
75. Bergers, G. etal. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2, 737-744 (2000).
76. Suzuki, M., Raab, G., Moses, M. A., Fernandez, C. A. & Klagsbrun, M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J. Biol. Chem. 272, 31730-31737 (1997).
77. Levi, E. et al. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc. Natl Acad. Sci. USA 93, 7069-7074 (1996).
78. Shull, M. M. et al. Targeted disruption of the mouse transforming growth factor-β 1 gene results in multifocal inflammatory disease. Nature 359, 693-699 (1992).
79. Kulkarni, A. B. & Karlsson, S. Transforming growth factor-β 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. Am. J. Pathol. 143, 3-9 (1993).
80. 6 binds and activates latent TGFβ1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96, 319-328 (1999).
81. Maeda, S., Dean, D. D., Gomez, R., Schwartz, Z. & Boyan, B. D. The first stage of transforming growth factor β1 activation is release of the large latent complex from the extracellular matrix of growth plate chondrocytes by matrix vesicle stromelysin-1 (MMP-3). Calcif Tissue Int. 70, 54-65 (2002).
82. Karsdal, M. A. et al. Matrix metalloproteinase-dependent activation of latent transforming growth factor-β controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J. Biol. Chem. 277, 44061-44067 (2002).
83. Fantuzzi, G. et al. Response to local inflammation of IL-1β-converting enzyme-deficient mice. J. Immunol. 158, 1818-1824 (1997).
84. Schonbeck, U., Mach, F. & Libby, P. Generation of biologically active IL-1β by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1β processing. J. Immunol. 161, 3340-3346 (1998).
85. Ito, A. et al. Degradation of interleukin 1β by matrix metalloproteinases. J. Biol. Chem. 271, 14657-14660 (1996).
86. Gearing, A. J. H. et al. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 370, 555-557 (1994).
87. Black, R. A. et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 385, 729-733 (1997).
88. Moss, M. L. et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 385, 733-736 (1997).
89. Mohan, M. J. et al. The tumor necrosis factor-α converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity Biochemistry 41, 9462-9469 (2002).
90. English, W. R. et al. Membrane type 4 matrix metalloproteinase (MMP 17) has tumor necrosis factor-α convertase activity but does not activate pro-MMP2. J. Biol. Chem. 275, 14046-14055 (2000).
91. Visse, R. & Nagase, H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92, 827-839 (2003).
92. Qi, J. H. et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nature Med. 9, 407-415 (2003).
93. Seo, D. W. et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 114, 171-180 (2003).
94. Oh, J. et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107, 789-800 (2001).
95. Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392 (2002).
96. Overall, C. M. & Lopez-Otin, C. Strategies for MMP inhibition in cancer; innovations for the post-trial era. Nature Rev. Cancer 2, 657-672 (2002).
97. Mott, J. D. et al. Post-translational proteolytic processing of procollagen C-terminal proteinase enhancer releases a metalloproteinese inhibiton J. Biol. Chem. 275, 1384-1390 (2000).
98. Belaaouaj, A. et al. Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nature Med. 4, 615-618 (1998).
99. Liu, Z. et al. The serpin α1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 102, 647-655 (2000). Using an experimental model of blister formation, this paper shows that MMP9 contributes to inflammation-mediated tissue damage by cleaving and inactivating the serpin α1-antiproteinase (a potent inhibitor of neutrophil elastase).
100. Lochter, A. et al. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J. Cell Biol. 139, 1861-1872 (1997).
101. Sympson, C. J. et al. Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression. J. Cell Biol. 125, 681-693 (1994).
102. Haro, H. et al. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-α in a model of herniated disc resorption. J. Clin. Invest. 105, 143-150 (2000).
103. Asahi, M. et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J. Neurosci. 21, 7724-7732 (2001).
104. Lelongt, B. et al. Matrix metalloproteinase 9 protects mice from anti-glomerular basement membrane nephritis through its fibrinolytic activity. J. Exp. Med. 193, 793-802 (2001).
105. Larsen, P. H., Wells, J. E., Stallcup, W. B., Opdenakker, G. & Yong, V. W. Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J. Neurosci. 23, 11127-11135 (2003).
106. Churg, A. et al. Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-α release. Am. J. Respir. Crit. Care Med. 187, 1083-1089 (2003).
107. Hotary, K. B. et al. Matrix metalloproteinases (MMPs) regulate fibrin-invasive activity via MT1-MMP-dependent and -independent processes. J. Exp. Med. 195, 295-308 (2002).
108. Endo, K. et al. Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J. Biol. Chem. 278, 40764-40770 (2003).
109. Koshikawa, N. et al. Proteolytic processing of laminin-5 by MT1-MMP in tissues and its effects on epithelial cell morphology. FASEB J. 18, 364-366 (2004).
110. Catarina, J. J. et al. Enamelysin (matrix metalloproteinase 20)-deficient mice display an amelogenesis imperfecta phenotype. J. Biol. Chem. 277, 49598-49604 (2002).
111. Billinghurst, R. C. et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J. Clin. Invest. 99, 1534-1545 (1997).
112. Otterness, I. G. et al. Detection of collagenase-induced damage of collagen by 9A4, a monoclonal C-terminal neoepitope antibody. Matrix Biol. 18, 331-341 (1999).
113. Wu, W. et al. Sites of collagenase cleavage and denaturation of type II collagen in aging and osteoarthritic articular cartilage and their relationship to the distribution of matrix metalloproteinase 1 and matrix metalloproteinase 13. Arthritis Rheum. 46, 2087-2094 (2002).
114. Hotary, K. B. et al. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 114, 33-45 (2003).
115. Balbin, M. et al. Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J. Biol. Chem. 276, 10253-10262 (2001).
116. Cossins, J., Dudgeon, T. J., Catlin, G., Gearing, A. J. & Clements, J. M. Identification of MMP-18, a putative novel human matrix metalloproteinase. Biochem. Biophys. Res. Commun. 228, 494-498 (1996).
117. Stolow, M. A. et al. Identification and characterization of a novel collagenase in Xenopus laevis: possible roles during frog development. Mol. Biol. Cell 7, 1471-1483 (1996).
118. Clark, H. F. et al. The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 13, 2265-2270 (2003).
119. Itoh, T. et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58. 1048-1051 (1998).
120. Kato, T. et al. Diminished corneal angiogenesis in gelatinase A-deficient mice. FEBS Lett. 508, 187-190 (2001).
121. Ohno-Matsui, K. et al. Reduced retinal angiogenesis in MMP-2-deficient mice. Invest. Ophthalmol Vis. Sci. 44, 5370-5375 (2003).
122. Berglin, L. et al. Reduced choroidal neovascular membrane formation in matrix metalloproteinase-2-deficient mice. Invest. Ophthalmol. Vis. Sci. 44, 403-408 (2003).
123. Wang, M. et al. Matrix metalloproteinase deficiencies affect contact hypersensitivity: stromelysin-1 deficiency prevents the response and gelatinase B deficiency prolongs the response. Proc. Natl Acad. Sci. USA 96, 6885-6889 (1999).
124. Warner, R. L. et al. Role of stromelysin 1 and gelatinase B in experimental acute lung injury. Am. J. Respir. Cell Mol. Biol. 24, 537-544 (2001).
125. Silence, J., Lupu, F., Collen, D. & Lijnen, H. R. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler. Thromb. Vasc. Biol. 21, 1440-1445 (2001).
126. Kure, T. et al. Corneal neovascularization after excimer keratectomy wounds in matrilysin-deficient mice. Invest. Ophthalmol. Vis. Sci. 44, 137-144 (2003).
127. Dubois, B. et al. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotising tail lesions. J. Clin. Invest. 104, 1507-1515 (1999).
128. Dubois, B. et al. Gelatinase B deficiency protects against endotoxin shock. Eur. J. Immunol. 32, 2163-2171 (2002).
129. Ratzinger, G. et al. Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin. J. Immunol. 168, 4361-4371 (2002).
130. Liu, Z. et al. Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. J. Exp. Med. 188, 475-482 (1998).
131. Vu, T. H. et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93, 411-422 (1998).
132. Coussens, L. M., Tinkle, C. L., Hanahan, D. & Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481-490 (2000).
133. Johnson, C., Sung, H. J., Lessner, S. M., Fini, M. E. & Galis, Z. S. Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: potential role in capillary branching. Circ. Res. 94, 262-268 (2004).
134. McMillan, S. J. et al. Matrix metalloproteinase-9 deficiency results in enhanced allergen-induced airway inflammation. J. Immunol. 172, 2586-2594 (2004).
135. Cataldo, D. D. et al. Matrix metalloproteinase-9 deficiency impairs cellular infiltration and bronchial hyperresponsiveness during allergen-induced airway inflammation, Am. J. Pathol. 161, 491-498 (2002).
136. Lanone, S. et al. Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and-12 in IL-13-induced inflammation and remodeling. J. Clin. Invest. 110, 463-474 (2002).
137. Luttun, A. et al. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation 109, 1408-1414 (2004).
138. Longo, G. M. et al. Matrix metalloproteinase 2 and 9 work in concert to produce aortic aneurysms, J. Clin. Invest. 110, 625-632 (2002).
139. Pyo, R. et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J. Clin. Invest. 105, 1641-1649 (2000).
140. Asahi, M. at al. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J. Cereb. Blood Flow Metab. 20, 1681-1689 (2000).
141. Lambert, V. et al. MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB J. 17, 2290-2292 (2003).
142. Shipley, J. M., Wesselschmidt, R. L., Kobayashi, D. K., Ley, T. J. & Shapiro, S. D. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc. Natl Acad. Sci. USA 93, 3942-3946 (1996).
143. Wells, J. E. et al. An adverse role for matrix metalloproteinase 12 after spinal cord injury in mice. J. Neurosci. 23, 10107-10115 (2003).
144. Warner, R. L. et al. The role of metalloelastase in immune complex-induced acute lung injury. Am. J. Pathol. 158, 2139-2144 (2001).